The latest data point for CVS's EPS Diluted in Q1'26 stands at 2.3 USD, reflecting a solid recovery and positive year-over-year growth of 63.1%. This marks an improvement from the prior quarter's 2.32 USD in Q4'25, indicating stabilized profitability amid recent volatility. Over the period from Q2'23 to Q1'26, EPS Diluted has exhibited a volatile trend, starting at 1.48 USD and peaking at 1.75 USD in Q3'23 before declining sharply to a low of -3.13 USD in Q3'25, driven by significant operational challenges. Year-over-year growth has been erratic, with notable declines such as -96% in Q3'24 and a drastic -4,571% in Q3'25, contrasted by recoveries like 167% in Q3'23 and 77% in Q4'25, suggesting underlying pressures in costs or revenues that have eased in the most recent quarters. Overall, the bar chart highlights inconsistent performance, while the overlaid line chart for growth underscores the need for sustained improvements to achieve stability.